TREM2 is associated with increased risk for Alzheimer’s disease in African Americans

Table 1 Results of the joint-analysis of 6 follow-up SNPs in TREM2

Variant	SNP	Position	AD cases			Controls			p	OR (95% CI)	Missing (%)	SIFT	PolyPhen-2
Variant	SNP	Position	No. of cases	No. of carriers	MAF (%)	No. of controls	No. of carriers	MAF (%)	p	OR (95% CI)	Missing (%)	SIFT	PolyPhen-2
p.R47H	rs75932628	6:41129252	899	2	0.11	2,471	3	0.06	0.61	1.83 (0.31-10.98)	0.7	Tolerated	Damaging
p.R62H	rs143332484	6:41129207	899	3	0.17	2,476	11	0.22	1	0.75 (0.20-2.69)	0.5	Tolerated	Benign
p.D87N	rs142232675	6:41129133	888	1	0.06	2,473	2	0.04	1	1.39 (0.13-15.37)	0.9	Tolerated	Damaging
p.E151K	rs79011726	6:41127561	867	6	0.35	2,467	7	0.16	0.22	2.14 (0.74-6.17)	1.7	Tolerated	Damaging
p.W191X	rs2234258	6:41126429	884	68	3.96	2,475	145	2.97	0.08‡	1.35 (0.97-1.87)	1	NA	NA
p.L211P	rs2234256	6:41126655	888	210	12.67	2,472	529	11.1	0.01‡	1.27 (1.05-1.54)	1	Tolerated	Benign

These analyses only used samples from Washington University, Mayo Clinic, Indiana University, WHICAP, and Emory University. Positions are relative to the human genome build GRCh37. The Fisher’s exact test was used to calculate the p values and effect sizes for p.R47H, p.R62H, p.D87N, and p.E151K using PLINK. ‡Multivariate logistic regression was performed to evaluate the association of p.W191X and p.L211P with AD risk adjusting for age, gender, APOE genotype, and cohorts.

ISSN: 1750-1326